CytoDyn (CYDY) Long-Term Deferred Tax (2012 - 2023)

CytoDyn's Long-Term Deferred Tax history runs 6 years deep, the most recent figure standing at $128.6 million for Q2 2023.

• Quarterly Long-Term Deferred Tax rose 9.3% year-over-year to $128.6 million in Q2 2023, while the trailing twelve-month figure through May 2023 was $128.6 million (up 9.3% YoY) and the FY2023 annual result came in at $128.6 million, up 9.3% from the prior year.
• Long-Term Deferred Tax was $128.6 million for Q2 2023 at CytoDyn, up from $117.6 million in the prior quarter.
• Across five years, Long-Term Deferred Tax topped out at $128.6 million in Q2 2023 and bottomed at $60.1 million in Q2 2020.
• A 4-year average of $97.4 million and a median of $100.4 million in 2021 frame the typical range for Long-Term Deferred Tax.
• Annual changes were most pronounced in 2022 — Long-Term Deferred Tax surged 41.3% — and 2023, when it grew 9.3%.
• CytoDyn's Long-Term Deferred Tax stood at $60.1 million in 2020, then soared by 38.51% to $83.3 million in 2021, then surged by 41.3% to $117.6 million in 2022, then grew by 9.3% to $128.6 million in 2023.
• Business Quant data shows CYDY's Long-Term Deferred Tax at $128.6 million in Q2 2023, $117.6 million in Q2 2022, and $83.3 million in Q2 2021.